Freenome Highlights Improved SimpleScreen CRC Performance Data At ACG 2026; Stock Up

(RTTNews) - Freenome, Inc. (FRNM), a company that develops blood tests for early cancer detection, announced it will present late-breaking data on an updated version of its SimpleScreen CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville.

Freenome's lead product, SimpleScreen CRC, is a blood-based screening test designed to detect colorectal cancer in average-risk adults. The company is also developing early-detection tests for lung cancer and other cancers.

The FDA approved the first-generation version of SimpleScreen CRC in July 2026, and Freenome's partner, Abbott Cancer Diagnostics, commercially launched the test in the United States in late September 2026.

Freenome conducted a pivotal clinical validation study to assess enhancements to the assay and algorithm used in the updated version of SimpleScreen CRC.

Key Findings According to the company, the updated test demonstrated 18.2% sensitivity for detecting advanced precancerous lesions (APLs), compared with 13.7% in the original PREEMPT CRC study.

Sensitivity for advanced precancerous lesions (APLs) with high-grade dysplasia (HGD) improved to 41.9% with the updated test, up from 30.5% previously reported.

According to Freenome, the sensitivity rates observed for APLs and APLs with HGD are the highest reported for a non-invasive blood-based screening test in a prospective registrational pivotal clinical study.

The updated test also improved sensitivity across all advanced precancerous lesion (APL) subtypes, including villous or tubulovillous adenomas, adenomas measuring 10 mm or larger, sessile serrated lesions or polyps measuring 10 mm or larger, and traditional serrated adenomas.

Overall, the test demonstrated 80.4% sensitivity for detecting colorectal cancer (CRC). Specificity among individuals with no findings on colonoscopy was 90% according to the company.

Aasma Shaukat, professor of medicine at NYU Grossman School of Medicine and co-lead principal investigator on the PREEMPT CRC study, will present the data on Wednesday, October 14, 2026.

CEO Quote "These results suggest that our blood-based screening test may detect precancerous lesions with clinically meaningful sensitivity," said Aaron Elliott, CEO of Freenome. Stock Performance The company has traded between $9.95 and $17.50 over the last year. The stock closed Friday (October 9, 2026) at $15.78, up 0.19%.

In overnight trading, shares rose 3.42% to $16.32.

For more such biotechstock news visit www.rttnews.com.